Trospium Chloride/Xanomeline

曲司氯铵/呫诺美林

Report date: 2026/05/14 20:00:28

Base Information

Drug NameTrospium Chloride/Xanomeline
Drug Alias NameTrospium Chloride+XanomelineXanomeline+trospium chlorideTrospium chloride/LY 246708Trospium chloride+LY 246708Xanomeline/trospium chloride +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M4 agonistsMuscarinic acetylcholine receptor M1 agonistsMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M4
Therapy Area/IndicationsBipolar I DisorderSchizophreniaPsychotic Disorders +[10] 
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryUnited States
Original Approved Date2024/09/26
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsYes Trospium Chloride
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPureTech Health PLC
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdUniversity of Texas Southwestern Medical Center +[7] 
Inactive CompaniesKaruna Pharmaceuticals IncZai Lab (Shanghai) Co LtdNew York State Psychiatric Institute
Active IndicationsBipolar I DisorderSchizophreniaPsychotic Disorders +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A